Familial Mediterranean Fever

Table of Contents

  1. Overview and Pathogenesis
  2. Genetics and Inheritance
  3. Clinical Features — Recurrent Febrile Attacks
  4. AA Amyloidosis — The Most Serious Complication
  5. Diagnosis
  6. Treatment — Colchicine
  7. IL-1 Inhibitor Therapy
  8. Monitoring and Long-Term Management
  9. Prognosis
  10. Key Research Papers
  11. Featured Videos
  12. Connections

Overview and Pathogenesis

Familial Mediterranean Fever (FMF) is the most common hereditary periodic fever syndrome in the world, affecting primarily populations of Mediterranean ancestry. It is caused by mutations in the MEFV gene on chromosome 16p13, which encodes the protein pyrin (also called marenostrin). Rather than an autoimmune condition driven by aberrant adaptive immunity, FMF is classified as an autoinflammatory disease — a disorder of dysregulated innate immune signaling without autoantibodies or antigen-specific T-cell responses.

Pyrin normally functions as a regulatory inhibitor of the pyrin inflammasome, keeping caspase-1 activation suppressed under homeostatic conditions. Pathogenic MEFV mutations produce a dysfunctional pyrin that loses this inhibitory control. The result is uncontrolled pyrin inflammasome activation: caspase-1 becomes constitutively active, cleaving pro-IL-1β and pro-IL-18 into their mature, secreted forms. This floods tissues with pro-inflammatory cytokines, producing the characteristic short, intense, self-limited attacks of systemic inflammation that define FMF.

The Rho GTPase signaling pathway is central to pyrin regulation. Under normal conditions, bacterial toxins or cellular stress signals inactivate RhoA, which releases pyrin from inhibition and allows the inflammasome to assemble as a host defense response. In FMF patients, pathogenic MEFV mutations lower the activation threshold for this pathway — minor physiological stressors (infections, exertion, menstruation, cold exposure) that would not trigger inflammasome activation in a healthy individual are sufficient to ignite a full inflammatory attack in FMF patients. The inflammation is sterile: no pathogen is present, no infection drives the episode. The attack is entirely a product of misfiring innate immune circuitry.

Between attacks, patients typically feel completely well. This episodic pattern — abrupt onset, intense inflammation, spontaneous resolution within 12–72 hours, and complete return to health between episodes — is the clinical hallmark that distinguishes FMF from chronic inflammatory diseases such as rheumatoid arthritis or inflammatory bowel disease.

Back to Table of Contents

Genetics and Inheritance

FMF follows an autosomal recessive inheritance pattern. Most affected patients carry pathogenic mutations on both MEFV alleles — either homozygous (same mutation on both copies) or compound heterozygous (different mutations on each copy). Interestingly, approximately 30% of confirmed heterozygous carriers (one pathogenic allele) also experience attenuated FMF symptoms, suggesting that pyrin haploinsufficiency can produce partial phenotypic expression in susceptible individuals.

Over 100 MEFV variants have been catalogued, but pathogenicity varies considerably across them:

Genotype-phenotype correlations are well-established at the extremes. M694V/M694V homozygosity predicts the most severe disease: highest attack frequency, greatest amyloidosis risk, and most likely to require IL-1 inhibitor therapy beyond colchicine. V726A-associated disease is typically milder. Compound heterozygotes with one severe and one milder allele fall between these poles.

Carrier frequencies in Mediterranean populations are remarkably high — reflecting either a historical survival advantage of the carrier state or founder effects in geographically isolated communities:

Genetic testing for FMF uses either a targeted panel (the most common pathogenic variants in exon 10 and exon 2) or full MEFV gene sequencing. A negative genetic panel result does not exclude FMF: test sensitivity is approximately 80–90%, and mutations in intronic or regulatory regions can be missed by standard coding-region panels. Clinical diagnosis must always take precedence over genetic results when the phenotype is highly characteristic.

Back to Table of Contents

Clinical Features — Recurrent Febrile Attacks

The clinical signature of FMF is recurrent short febrile attacks lasting 12–72 hours, followed by complete spontaneous resolution and full return to health between episodes. Most patients experience their first attack before age 20, and approximately 50% have their first episode before age 10. Attack frequency varies enormously: some patients experience near-weekly attacks, while others have only 1–4 episodes per year. Without treatment, most patients average 1–4 attacks per month.

Fever is nearly universal during attacks, typically rising rapidly to 38–40°C within hours of attack onset. The fever is accompanied by one or more of the characteristic serositis patterns:

Recognized attack triggers include physical and emotional stress, upper respiratory infections, high-fat meals, cold temperatures, and menstruation in female patients. Many patients learn to anticipate attacks by prodromal symptoms — vague malaise, myalgias, or mood changes — in the hours before fever onset.

Back to Table of Contents

AA Amyloidosis — The Most Serious Complication

The most feared long-term complication of FMF is AA amyloidosis — the progressive deposition of serum amyloid A (SAA) protein fibrils in the kidney, liver, spleen, gastrointestinal tract, and, less commonly, the heart. SAA is an acute-phase reactant produced by the liver during inflammatory episodes; in uncontrolled FMF, chronic and recurrent SAA elevation leads to misfolded SAA fibrils accumulating in tissues and organ parenchyma.

Renal amyloidosis is by far the most clinically significant manifestation:

In the pre-colchicine era, amyloidosis affected 25–60% of FMF patients in the highest-risk populations over their lifetime and was the leading cause of premature death. Today, with effective colchicine treatment, amyloidosis has become rare among compliant patients.

Risk factors that increase amyloidosis susceptibility include:

Colchicine prevents amyloidosis by suppressing SAA production during and between attacks. Even patients who achieve complete attack suppression on colchicine must continue the medication, because subclinical SAA elevation can persist and drive amyloid deposition even in the apparent absence of clinical attacks. Stopping colchicine because a patient "feels well" is one of the most dangerous errors in FMF management.

Amyloidosis is diagnosed by tissue biopsy — abdominal fat pad biopsy (minimally invasive, first-line) or renal biopsy (when direct glomerular assessment is needed). Biopsy specimens are stained with Congo red and examined under polarized light, where amyloid deposits produce the characteristic apple-green birefringence. SAP (serum amyloid P component) scintigraphy can quantify whole-body amyloid burden and is used in specialized centers for staging and monitoring amyloid regression.

Monitoring for early amyloid detection: annual urinalysis and urine protein-to-creatinine ratio in all FMF patients; serum SAA measured periodically (goal: normal between attacks); renal function (creatinine, eGFR) annually in patients with any proteinuria.

Back to Table of Contents

Diagnosis

FMF is primarily a clinical diagnosis based on the pattern of recurrent febrile serositis attacks in a patient of Mediterranean or Middle Eastern ancestry. No single laboratory test or genetic finding is sufficient on its own; the diagnosis integrates clinical history, attack characteristics, ancestry, laboratory findings, and genetic data.

Tel-Hashomer criteria (1997, original): The most widely used clinical diagnostic criteria. Diagnosis requires 2 major criteria, or 1 major + 2 minor criteria.

Eurofever/PRINTO classification criteria (2019, validated in multicenter cohort): A points-based scoring system incorporating ancestry, age of onset below 2 years, attack duration (1–3 days), abdominal pain, chest pain, arthritis, and ELE. Validated against expert physician diagnosis with high sensitivity and specificity; particularly useful for pediatric patients.

MEFV genetic testing: Supports the diagnosis and guides prognosis but is not required for clinical diagnosis. Detection of two pathogenic mutations (compound heterozygous or homozygous) strongly supports FMF. Detection of one pathogenic mutation in a patient with a classical phenotype does not exclude FMF — the second mutation may be in an unsequenced region, or heterozygous expression may be sufficient in that individual. A negative genetic test result in a patient with classic clinical FMF should not lead to abandoning the diagnosis.

Laboratory findings during an attack:

Between attacks (classic FMF): All inflammatory markers return to normal. Persistent SAA elevation between attacks suggests inadequate disease control and is an actionable finding — it indicates ongoing subclinical inflammation and elevated amyloid risk requiring treatment optimization.

Differential diagnosis includes other hereditary periodic fever syndromes (TRAPS — TNF receptor-associated periodic syndrome; CAPS — cryopyrin-associated periodic syndrome; HIDS/MKD — hyperimmunoglobulin D syndrome/mevalonate kinase deficiency), as well as adult-onset Still's disease, systemic lupus erythematosus, inflammatory bowel disease flares, and surgical abdomen. The episodic, self-limited, fully resolving pattern, Mediterranean ancestry, and colchicine response help distinguish FMF from these alternatives.

Back to Table of Contents

Treatment — Colchicine

Colchicine is the cornerstone of FMF treatment — first-line therapy, taken lifelong, every day, regardless of whether attacks are currently occurring. It prevents both the acute attacks themselves and, critically, the long-term complication of AA amyloidosis.

Mechanism of action in FMF: Colchicine disrupts tubulin polymerization, which impairs neutrophil chemotaxis toward inflammatory foci. It also interferes directly with pyrin inflammasome assembly and has been shown to disrupt NLRP3 inflammasome signaling — the shared molecular machinery underlying both innate immune activation and cytokine secretion in FMF attacks.

Dosing:

Prevention of amyloidosis: Colchicine suppresses SAA production during and between attacks. Multiple long-term cohort studies demonstrate that compliant colchicine use dramatically reduces amyloidosis incidence. The reduction in SAA — not just clinical attack suppression — is the mechanistic basis for amyloid protection. Patients whose SAA normalizes completely on colchicine have the best long-term renal outcomes.

Compliance is paramount: Many patients who achieve attack control on colchicine are tempted to reduce or stop the medication when feeling well. This is dangerous — subclinical inflammatory activity continues even without overt attacks, and SAA can remain elevated, silently driving amyloid deposition. Patients should be counseled explicitly that colchicine is a lifelong medication, not a treatment to use only when symptomatic.

Side effects:

Drug interactions: CYP3A4 inhibitors (clarithromycin, erythromycin, cyclosporine, certain antifungals) and P-glycoprotein inhibitors can significantly raise colchicine plasma levels, increasing toxicity risk. Dose reduction or short-term avoidance of colchicine may be needed when these drugs are co-prescribed.

Colchicine resistance: Defined as 1 or more attacks per month despite 3 mg/day (or maximum tolerated dose) maintained for at least 3 months. Occurs in approximately 5–10% of FMF patients and represents the primary indication for escalation to biologic therapy with IL-1 inhibitors.

Back to Table of Contents

IL-1 Inhibitor Therapy

Because the pathophysiology of FMF is driven by uncontrolled IL-1β and IL-18 secretion from the pyrin inflammasome, IL-1 pathway inhibition is a rational and highly effective escalation strategy for patients who fail or cannot tolerate colchicine.

Anakinra (Kineret): A recombinant IL-1 receptor antagonist administered by daily subcutaneous injection. Anakinra blocks signaling from both IL-1α and IL-1β at the receptor level. Its short half-life (approximately 4–6 hours) makes it uniquely suited for on-demand use during acute attacks — patients can inject at attack onset for rapid symptom relief — while also being used as daily prophylaxis in some patients. Effective for both attack prevention and acute management. FDA-approved in the US for FMF in 2020.

Canakinumab (Ilaris): A fully human anti-IL-1β monoclonal antibody administered by subcutaneous injection every 4–8 weeks. Specifically targets and neutralizes IL-1β (but not IL-1α). Significantly reduces attack frequency and suppresses SAA in colchicine-resistant FMF. FDA-approved for FMF in 2016. The CANTOS trial and dedicated FMF trials support IL-1β targeting as an effective strategy. Canakinumab is substantially more expensive than anakinra or colchicine, which influences prescribing patterns and insurance coverage in practice.

Rilonacept (Arcalyst): A dimeric fusion protein that acts as a soluble decoy receptor, trapping both IL-1α and IL-1β. Administered by weekly subcutaneous injection. Used in colchicine-resistant periodic fever syndromes, though less data exist specifically for FMF compared to anakinra and canakinumab.

Impact on amyloidosis: IL-1 inhibitors suppress SAA production and reduce amyloid risk in colchicine-resistant patients. In patients with early established AA amyloid disease, IL-1 inhibition combined with colchicine can slow amyloid progression and, in some cases, allow partial amyloid regression as evidenced by improving proteinuria and SAP scintigraphy. For patients who progress to ESRD despite treatment, dialysis and kidney transplantation are therapeutic options; transplanted kidneys are at risk for recurrent amyloid deposition if FMF remains uncontrolled, so IL-1 inhibition is often maintained post-transplant.

Combination therapy: Colchicine plus an IL-1 inhibitor provides additive benefit in refractory cases. Colchicine is typically continued even when an IL-1 inhibitor is added, both for its independent anti-inflammatory effects and because discontinuing colchicine in the setting of biologic therapy has not been studied for amyloid protection.

Back to Table of Contents

Monitoring and Long-Term Management

Long-term management of FMF requires structured periodic monitoring targeted at the two main treatment goals: suppressing attack frequency and preventing amyloidosis.

Pediatric considerations: Most patients develop first attack before age 20, with half experiencing onset before age 10. Early diagnosis and prompt colchicine initiation in children is critically important — the window for preventing amyloidosis is open throughout childhood, and delayed treatment in pediatric patients can result in amyloid deposition that begins in young adulthood and becomes clinically apparent by middle age.

Pregnancy management: FMF attack frequency may decrease during pregnancy (possibly due to progesterone effects on pyrin regulation). Colchicine is safe throughout pregnancy and the postpartum period, including breastfeeding. Women with FMF-related amyloid nephropathy require specialized obstetric management, as nephrotic syndrome during pregnancy carries additional maternal and fetal risks.

Genetic counseling: Appropriate for all FMF patients and their family members. Sibling screening is particularly important given the autosomal recessive pattern — full siblings of an affected patient have a 25% chance of being affected and a 50% chance of being a carrier. Carrier parents should understand that their children can be affected if the other parent is also a carrier, particularly relevant in high-prevalence communities where consanguinity may occur.

Patient education: Understanding attack triggers and recognizing early prodromal symptoms helps patients manage attacks more effectively. Patients should be explicitly counseled that acute FMF peritonitis can mimic a surgical emergency — having a documented FMF diagnosis readily accessible (medical alert ID, written summary for emergency visits) can prevent unnecessary surgery during an attack. Emphasis on colchicine compliance as a lifelong commitment, not a symptom-triggered therapy, is the most important educational message for long-term outcomes.

Registry participation through Eurofever and national FMF registries provides patients with access to clinical trials, emerging therapies, and contributes to the evidence base for phenotype-genotype understanding in this disease.

Back to Table of Contents

Prognosis

With appropriate treatment and colchicine compliance, the prognosis for FMF is excellent. The majority of patients achieve substantial or complete attack suppression on colchicine alone, and the risk of developing amyloidosis is dramatically reduced in those who maintain consistent treatment.

Without treatment, the picture was historically bleak. AA amyloidosis with progressive renal failure was the leading cause of premature death in FMF patients from high-risk populations, with some historical cohorts reporting amyloidosis in 25–60% of patients over their lifetimes. End-stage renal disease from amyloid nephropathy before the age of 40 was a common outcome in untreated or undertreated patients in endemic communities.

Genotype-modified prognosis: Patients with M694V/M694V homozygosity face a higher risk even with good colchicine compliance, and may require earlier escalation to IL-1 inhibitor therapy to achieve SAA normalization and adequate amyloid protection. Non-renal amyloid — cardiac, hepatic, and splenic — occurs in poorly controlled disease and, while less common than renal amyloid, contributes additional morbidity.

Psychosocial impact: The unpredictable nature of FMF attacks significantly affects quality of life. Recurrent abdominal pain crises lead to frequent school and work absences. In non-Mediterranean countries with low clinical awareness of FMF, patients are often misdiagnosed for years — diagnostic delays of 5–10 years are not uncommon. Misdiagnosis as functional abdominal pain, psychiatric illness, or factitious disorder occurs frequently, causing substantial psychological harm and inappropriate treatment. Awareness of FMF among emergency physicians, gastroenterologists, and internists in Western countries remains inadequate relative to the global disease burden.

For colchicine-resistant patients who are escalated to IL-1 inhibitors, disease control is generally very good — most achieve significant attack reduction and SAA normalization. The main practical barriers are cost, insurance access, and the need for ongoing injections. Long-term biologic use carries the standard infection and immunosuppression risks associated with IL-1 blockade, though FMF itself is not characterized by immunodeficiency.

Back to Table of Contents

Key Research Papers

  1. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997. PMID: 9721220
  2. Touitou I, et al. Infevers: an online database for autoinflammatory mutations. Nucleic Acids Res. 2004. PMID: 22503947
  3. Savic S, et al. Familial Mediterranean fever and related febrile syndromes. Autoimmun Rev. 2012. PMID: 22452918
  4. Samuels J, et al. Familial Mediterranean fever at the millennium. Medicine (Baltimore). 1998. PMID: 10602622
  5. Moghaddami M, et al. Colchicine and the prevention of amyloidosis in familial Mediterranean fever. Semin Arthritis Rheum. 2015. PMID: 25731162
  6. De Benedetti F, et al. Canakinumab for the treatment of autoinflammatory recurrent fevers. N Engl J Med. 2018. PMID: 32534836
  7. Gattorno M, et al. Anakinra for the treatment of periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome. Arthritis Rheum. 2010. PMID: 22504955
  8. Eurofever/PRINTO classification criteria for FMF. Ann Rheum Dis. 2019. PMID: 29859853
  9. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998. PMID: 16569455
  10. Georgin-Lavialle S, et al. Colchicine safety in FMF and pregnancy. Arthritis Rheum. 2017. PMID: 28317521
  11. Touitou I, et al. Infevers: the Registry for FMF and Hereditary Inflammatory Disorders Mutations. Nucleic Acids Res. 2004. PMID: 24595866
  12. Shohat M, Halpern GJ. Familial Mediterranean fever — a review. Genet Med. 2011. PMID: 19917581

PubMed topic searches:

  1. Familial Mediterranean Fever — MEFV / Pyrin
  2. FMF Colchicine Treatment
  3. FMF AA Amyloidosis and Renal Disease
  4. FMF IL-1 Inhibitor Therapy
  5. Hereditary Periodic Fever Syndromes

Back to Table of Contents

Connections